We are live on ! Find out more
IPHA icon

Innate Pharma
IPHA

9 hedge funds and large institutions have $235K invested in Innate Pharma in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.1% less ownership

Funds ownership: 0.3% → 0.2% (-0.1%)

18% less funds holding

Funds holding: 11 → 9 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less capital inflows, than outflows

Capital inflows: $3 | Capital outflows: $154K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 6

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Caitong International Asset Management
Caitong International Asset Management
Hong Kong
+$3

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$80.6K
2
Old Mission Capital
Old Mission Capital
Illinois
-$49.8K
3
Millennium Management
Millennium Management
New York
-$16.7K
4
Morgan Stanley
Morgan Stanley
New York
-$4.69K
5
GAMMA Investing
GAMMA Investing
California
-$1.36K

IPHA Hedge Fund Activity: Q1 2026 in Review

9 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2026, worth a combined $235K — down 51% from $483K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of IPHA and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 0 added.

The largest buyer was Caitong International Asset Management, opening a new position worth an estimated $3. The largest seller was Jane Street, cutting an estimated $80.6K.

  • 9 institutional investors held Innate Pharma (IPHA) as of Q1 2026, down from 11 in Q4 2025.
  • Funds reported $235K of Innate Pharma stock for Q1 2026, down 51% quarter-over-quarter.
  • 1 fund opened new Innate Pharma positions in Q1 2026 and 3 closed out, a net change of -2 holders.
  • The largest Innate Pharma buyer in Q1 2026 was Caitong International Asset Management, an estimated $3 added.
  • The largest Innate Pharma seller in Q1 2026 was Jane Street, an estimated $80.6K sold.

Based on aggregated 13F filings for Q1 2026.